Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2017, XLII/249: 110-115 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2017, XLII/249: 110-115

Title: Proteflazid® and local immunity in diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections 

Authors: Kaminsky V, Chernyshov V, Grynevych O, Benyuk V, Kornatskaya A, Shalko M, Usevich I, Revenko O, Shepetko M, Solomakha L. 

More details

04/249

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN ENGLISH.

Proteflazid® and local immunity in diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections


Kaminsky V1, Chernyshov V2, Grynevych O3, Benyuk V4, Kornatskaya A2, Shalko M1, Usevich I4, Revenko O2, Shepetko M3, Solomakha L3.

1Shupyk National Medical Academy for Post-graduate Education, Kyiv, Ukraine; 2State Institution „Institute of Pediatrics, Obstetrics and Gynecology of NAMS of Ukraine”, Kyiv; Ukraine; 3Scientific & Manufacturing Company “Ecopharm” Ltd, Kyiv, Ukraine; 4Bogomolets National Medical University, Kyiv, Ukraine

Reporting of clinical trials results for Proteflazid® in the drug formulation suppositories and vaginal swabs soaked in the solution of the drug to the local immunity of the female reproductive tract.
The aim of study
was to examine the state of local immunity in the reproductive tract of women with sexually transmitted diseases caused by human papillomavirus, herpes viruses (Type 1, 2) and mixed infection (herpes viruses + chlamydia).
Material and methods
. The trials involved 216 women with viral sexually transmitted diseases: Cervical Dysplasia associated with papillomavirus infection (HPV) (Group 1); Herpes genitalis type 1 (HSV- 1) and type 2 (HSV-1) (Group 2); mixed infection – HSV-1, HSV-2 and chlamydia (Group 3).
Results
. Treatment results have confirmed that Proteflazid® contributes to sustainable performance improvement of basic factors of local immunity – sIgA, lysozyme and complement component C3 in the cervical mucus for all three groups of women.
Conclusions
. Proteflazid® enhances level of local immunity markers (sIgA, lysozyme, C3 complement component) and improves their ratios. Also it intensifies anticontagious activity of mucosal protection and female reproductive system as whole, during treatment diseases caused by human papillomavirus, herpesvirus and mixed urogenital infections (herpesvirus and chlamydia).

Key words: local immunity, papillomavirus, herpes, mixed infection, Proteflazid®

Pol Med J, 2017; XLII (249); 110–115